Earnings Report - IDEXX Laboratories, Inc. is set to release its third-quarter earnings results on November 3, with analysts expecting earnings of $3.14 per share, an increase from $2.80 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $1.07 billion, compared to $975.54 million a year earlier [1] Recent Performance - On August 4, IDEXX Laboratories reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates [2] - Following the announcement, shares of IDEXX Laboratories rose 0.2% to close at $629.51 [2] Analyst Ratings - Stifel analyst Jonathan Block upgraded the stock from Hold to Buy, raising the price target from $640 to $700 [4] - UBS analyst Andrea Alfonso initiated coverage with a Neutral rating and a price target of $720 [4] - Morgan Stanley analyst Erin Wright maintained an Overweight rating and increased the price target from $722 to $765 [4] - Piper Sandler analyst David Westenberg maintained a Neutral rating and raised the price target from $510 to $700 [4] - JP Morgan analyst Chris Scott maintained an Overweight rating and increased the price target from $550 to $675 [4]

Earnings Reports - Williams Companies Inc (NYSE:WMB) is expected to report quarterly earnings of 51 cents per share on revenue of $2.89 billion [2] - Spirit AeroSystems Holdings Inc (NYSE:SPR) reported a loss of $4.87 per share with quarterly sales of $1.585 billion, missing the analyst consensus estimate of $1.923 billion [2] - Goodyear Tire & Rubber Co. (NASDAQ:GT) is anticipated to post quarterly earnings of 19 cents per share on revenue of $4.67 billion [2] - IDEXX Laboratories Inc. (NASDAQ:IDXX) is projected to report quarterly earnings of 3.13 per share on revenue of $1.07 billion [2] - ON Semiconductor Corp. (NASDAQ:ON) is expected to post quarterly earnings of 59 cents per share on revenue of $1.51 billion [2] Stock Performance - Williams shares rose 0.4% to close at $57.87 on Friday [2] - Spirit AeroSystems shares gained 1% to close at $36.69 on Friday [2] - Goodyear Tire shares rose 0.6% to $6.93 in after-hours trading [2] - IDEXX Laboratories shares rose 0.9% to $634.89 in after-hours trading [2] - ON Semiconductor shares gained 0.7% to $50.44 in after-hours trading [2]

Core Viewpoint - The article compiles significant research calls from Wall Street, highlighting upgrades for various companies based on their recent performance and outlook. Group 1: Company Upgrades - Jefferies upgraded Apple (AAPL) to Hold from Underperform with a price target of $246.99, up from $203.07, after September quarter revenue grew about 8% and gross margin came in at 47.2%, or about 0.5% better than expected including a $1.1B tariff [2] - Goldman Sachs upgraded Roblox (RBLX) to Buy from Neutral with a price target of $180, up from $155, following the Q3 earnings report, citing strength in bookings, revenue, and daily active user growth, with management optimistic about long-term scaling [2] - BTIG upgraded Unity (U) to Neutral from Sell and removed the prior $27 price target, noting healthy spending trends based on recent surveys of gaming and non-advertising professionals [2] - Piper Sandler upgraded Hershey (HSY) to Neutral from Underweight with an unchanged price target of $167, highlighting the company's plans to be "on-algorithm" in 2026 for better visibility [2] - Stifel upgraded Idexx Laboratories (IDXX) to Buy from Hold with a price target of $700, up from $640, expecting accelerated recurring revenue growth in the Companion Animal Group [2]

Core Viewpoint - Analysts expect Idexx Laboratories (IDXX) to report quarterly earnings of $3.14 per share, reflecting a year-over-year increase of 12.1%, with revenues projected at $1.07 billion, up 9.7% from the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 0.5% in the last 30 days, indicating a reassessment of initial estimates by covering analysts [1][2]. Revenue Estimates - Revenue from the Companion Animal Group (CAG) is expected to reach $981.37 million, representing a 10% increase from the prior-year quarter [4]. - Revenue from Other segments is projected at $4.48 million, indicating a 1.8% increase year-over-year [4]. - Revenue from Livestock and Poultry Diagnostics (LPD) is estimated at $30.45 million, reflecting a 5% increase from the previous year [5]. - Water revenue is expected to be $54.46 million, showing an 8.6% increase year-over-year [5]. - Revenue from the Companion Animal Group in the United States is projected at $654.89 million, indicating an 8.4% year-over-year change [5]. - International revenue from the Companion Animal Group is estimated at $324.70 million, reflecting a 12.8% increase [6]. - LPD International revenue is expected to be $24.64 million, indicating a 5.1% increase [6]. - Water International revenue is projected at $26.02 million, reflecting a 10.7% increase [6]. Gross Profit Estimates - Gross Profit for the Companion Animal Group (CAG) is expected to reach 61.4%, up from 61.0% reported in the same quarter last year [7]. - Gross Profit for Other segments is projected at 26.2%, compared to 49.9% reported in the previous year [7]. - Gross Profit for LPD is expected to be 50.4%, slightly down from 50.5% reported last year [8]. - Gross Profit for Water is projected at 69.6%, up from 69.3% reported in the same quarter last year [8]. Market Performance - Shares of Idexx have experienced a -0.7% change in the past month, contrasting with a +3.8% move of the Zacks S&P 500 composite [8].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Idexx Laboratories (IDXX) due to higher revenues, with a focus on how actual results will compare to estimates to influence stock price [1][2]. Earnings Expectations - Idexx is expected to report quarterly earnings of $3.14 per share, reflecting a year-over-year increase of +12.1%, with revenues projected at $1.07 billion, up 9.8% from the previous year [3]. - The earnings report is scheduled for release on November 3, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.46% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Idexx is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.23%, suggesting a bullish outlook on earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Idexx holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [12]. Historical Performance - Idexx has consistently surpassed consensus EPS estimates, achieving this in the last four quarters, including a +9.67% surprise in the most recent quarter [13][14]. Industry Context - In comparison, Edwards Lifesciences (EW) is expected to report earnings of $0.59 per share, indicating a year-over-year decline of -11.9%, with revenues projected at $1.5 billion, up 11.1% from the previous year [18]. - Edwards Lifesciences has a lower Earnings ESP of -1.22% and a Zacks Rank of 3, making it challenging to predict an earnings beat [19].

Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, but their Mid Cap Composite underperformed with a return of -3.2% net-of-fees compared to a 2.8% gain for the Russell Midcap Growth Index [1] - The focus on high-quality, profitable companies struggled in a risk-on environment during the quarter [1] Company Overview: IDEXX Laboratories, Inc. - IDEXX Laboratories, Inc. is a leader in diagnostics and information systems for veterinary, food, and water testing applications [3] - The company reported a one-month return of -1.74% and a 52-week gain of 38.06%, with shares closing at $637.13 on October 21, 2025, and a market capitalization of $50.97 billion [2] - IDEXX's revenue increased by 11% as reported and 9% organically in Q2 2025, despite weak veterinarian visits [4] Performance and Market Position - IDEXX Laboratories experienced strong earnings in Q3 2025, with accelerated organic revenue growth and rapid adoption of their latest premium instrument [3] - The number of hedge funds holding IDEXX shares decreased from 51 to 48 from the previous quarter, indicating a slight decline in popularity among institutional investors [4]

Core Insights - Hologic (HOLX) and Idexx Laboratories (IDXX) are both considered by investors interested in Medical - Instruments stocks, with a focus on determining which stock is more attractive to value investors [1] Valuation Metrics - Both HOLX and IDXX currently hold a Zacks Rank of 2 (Buy), indicating positive revisions to their earnings estimates and improving earnings outlooks [3] - HOLX has a forward P/E ratio of 16.05, while IDXX has a significantly higher forward P/E of 51.02 [5] - The PEG ratio for HOLX is 2.47, compared to IDXX's PEG ratio of 4.17, suggesting that HOLX may be undervalued relative to its expected earnings growth [5] - HOLX's P/B ratio is 3.3, while IDXX's P/B ratio is 35.29, further indicating that HOLX is more attractively valued [6] - Based on these valuation metrics, HOLX receives a Value grade of B, whereas IDXX receives a Value grade of D, suggesting that HOLX is the superior value option at this time [6]

Core Insights - IDEXX Laboratories, Inc. (IDXX) is scheduled to release its third-quarter 2025 results on November 3, before the market opens, with expectations of strong performance based on previous quarters [1][9] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $1.07 billion, reflecting a 9.8% increase from the previous year [2][9] - The Zacks Consensus Estimate for EPS is $3.14, indicating a rise of 12.1% year-over-year [2][9] Performance Drivers - The Companion Animal Group (CAG) is anticipated to significantly contribute to IDEXX's revenue, driven by strong global execution, higher price realization, and increased test volumes [4][9] - The adoption of innovations like the Catalyst Pancreatic Lipase and the IDEXX Cancer Dx diagnostic panel is expected to enhance revenue from CAG Diagnostics [5][9] - Robust placements of premium instruments, particularly the IDEXX inVue Dx Analyzer, are likely to support growth in diagnostic services and accessories [6][9] Segment Performance - CAG business revenues are projected to increase by 10% year-over-year in Q3 2025 [7] - The Water segment is expected to benefit from higher testing volumes in Europe and Asia Pacific, with an estimated 8.6% year-over-year growth [10] - The Livestock, Poultry, and Dairy (LPD) division is forecasted to see a 5% year-over-year increase in revenues, supported by high test volumes and favorable price realization [11] Earnings Expectations - IDEXX Laboratories has an Earnings ESP of +0.23%, indicating a higher likelihood of beating estimates [12] - The company currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [13]

Core Insights - IDEXX Laboratories, Inc. is valued at a market cap of $50.7 billion and is a leader in veterinary diagnostics and software solutions [1] - The company is set to announce its fiscal Q3 earnings for 2025, with analysts projecting a profit of $3.14 per share, reflecting a 12.1% increase from the previous year [2] - Analysts expect IDEXX to report an EPS of $12.61 for the current year, which is an 18.2% increase from fiscal 2024, with further growth anticipated [3] Financial Performance - In the last fiscal quarter, IDEXX reported quarterly revenue of $1.1 billion, a 10.6% year-over-year increase, and earnings per share of $3.63, a 48.8% increase from the same quarter last year [5] - The company raised its fiscal 2025 EPS guidance to a range of $12.40–$12.76, indicating strong profitability and reinforcing investor confidence [5] Stock Performance - IDEXX shares have increased by 33.2% over the past year, outperforming the S&P 500 Index's return of 13.4% and the Health Care Select Sector SPDR Fund's decline of 8% [4] - Wall Street analysts have a "Moderate Buy" rating on IDEXX, with a mean price target of $722.36, suggesting a potential upside of 13.4% from current levels [6]

Core Viewpoint - IDEXX Laboratories, Inc. is set to release its Q3 2025 financial results on November 3, 2025, before market opening, indicating the company's ongoing commitment to transparency and communication with investors [1] Financial Results Announcement - The financial results will be released before the market opens on November 3, 2025 [1] - An analyst conference call is scheduled to begin at 8:30 a.m. ET on the same day [1] - A live webcast of the conference call, along with a transcript of prepared remarks and the Q3 2025 Earnings Snapshot, will be accessible through a link on the IDEXX website [1]